BG
ACAD icon

BlackRock Group’s Acadia Pharmaceuticals ACAD Stock Holding History

BlackRock Group’s Portfolio ACAD Stock Details ACAD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		$2.59M Sell
89,888
-51,037
-36% -$1.35M ﹤0.01% 1583
2016
Q3 		$4.48M Buy
140,925
+14,698
+12% +$498K ﹤0.01% 1160
2016
Q2 		$4.1M Buy
126,227
+41,846
+50% +$1.4M ﹤0.01% 1174
2016
Q1 		$2.36M Buy
84,381
+24,237
+40% +$528K ﹤0.01% 1435
2015
Q4 		$2.14M Buy
60,144
+4,468
+8% +$157K ﹤0.01% 1445
2015
Q3 		$1.84M Buy
55,676
+9,461
+20% +$394K ﹤0.01% 1540
2015
Q2 		$1.94M Buy
46,215
+4,500
+11% +$174K ﹤0.01% 1576
2015
Q1 		$1.36M Buy
41,715
+11,630
+39% +$400K ﹤0.01% 1687
2014
Q4 		$955K Buy
30,085
+5,281
+21% +$150K ﹤0.01% 1907
2014
Q3 		$615K Sell
24,804
-360
-1% -$8.42K ﹤0.01% 2070
2014
Q2 		$569K Sell
25,164
-18,341
-42% -$383K ﹤0.01% 2149
2014
Q1 		$1.06M Buy
43,505
+21,472
+97% +$543K ﹤0.01% 1966
2013
Q4 		$550K Sell
22,033
-249,428
-92% -$5.88M ﹤0.01% 2199
2013
Q3 		$7.46M Sell
271,461
-294,300
-52% -$6.15M 0.01% 990
2013
Q2 		$10.3M Buy
+565,761
New +$7.79M 0.01% 855

Other funds holding ACAD

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return

BlackRock Group's ACAD Position: Q4 2016 in Review

BlackRock Group reduced its Acadia Pharmaceuticals (ACAD) stake by 36% in Q4 2016, selling an estimated $1.35M and leaving 89,888 shares worth $2.59M. The position accounts for ﹤0.01% of the portfolio, ranked #1583.

BlackRock Group first reported a position in ACAD in Q2 2013 and has held it in 15 quarters since. The position peaked at $10.3M in Q2 2013. 225 funds tracked by Wall St. Rank hold ACAD as of Q4 2016.

  • BlackRock Group held 89,888 shares of Acadia Pharmaceuticals worth $2.59M as of Q4 2016.
  • BlackRock Group sold 51,037 Acadia Pharmaceuticals shares in Q4 2016, an estimated $1.35M.
  • Acadia Pharmaceuticals made up ﹤0.01% of BlackRock Group's portfolio in Q4 2016, its #1583 holding.
  • BlackRock Group first reported a position in Acadia Pharmaceuticals in Q2 2013 and has held it in 15 quarters since.
  • BlackRock Group's Acadia Pharmaceuticals position peaked at $10.3M in Q2 2013.
  • 225 funds tracked by Wall St. Rank held Acadia Pharmaceuticals as of Q4 2016.

Based on BlackRock Group's 13F filing for Q4 2016, filed 10 Feb 2017.